Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. David T. Hung M.D. | Founder, President, CEO & Chairman | 1M | -- | 1958 |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer | 694.56k | -- | 1967 |
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer | 677.15k | -- | 1970 |
| Mr. Philippe Sauvage | Chief Financial Officer & Principal Financial Officer | -- | -- | 1977 |
| Mr. Moses Makunje CPA | VP of Finance and Principal Accounting & Financial Officer | -- | -- | 1979 |
| Stephen Dang | VP of Legal & Secretary | -- | -- | -- |
| Ms. Stacy Markel | Chief People Officer | -- | -- | 1965 |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer | 586.04k | -- | 1970 |
| Ms. Kerry A. Wentworth | Chief Regulatory Officer | -- | -- | 1973 |
| Ms. Colleen Sjogren | Chief Commercial Officer | -- | -- | 1970 |
Nuvation Bio Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 203
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
February 26, 2025 at 10:59 AM UTC - March 3, 2025 at 12:00 PM UTC
Nuvation Bio Inc. Earnings Date
Recent Events
August 12, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission